Boehringer sponsors UGC contest in diabetes awareness effort

Share this article:
Boehringer sponsors UGC contest in diabetes awareness effort
Boehringer sponsors UGC contest in diabetes awareness effort
Boehringer Ingelheim and the Diabetes Hands Foundation are seeking to raise awareness of diabetes with a contest inviting adults with diabetes to submit videos describing life with diabetes through one of the five senses.

Videos can run up to three minutes and “should express creativity and originality, be truthful and convey emotion in a compelling, evocative and personal way,” the sponsors said.

“Diabetes affects people's lives in profound and unexpected ways,” said Manny Hernandez, Diabetes Hands Foundation founder, in a statement. “We smell insulin, savor glucose tablets, feel the poke of lancing devices, react to our doctors words and see the life ahead of us. Diabetes is complex and we hope this video contest will help people express and share their diabetes experiences with the diabetes community as a whole as well as with people close to them.”

The contest, intended to coincide with World Diabetes Day on November 14, runs from September 28 to November 1. Three weekly finalists will be chosen based on unique views, average rating, quantity and quality of comments, creativity and originality. Prizes include kitchen scales, meter bags and books on living with diabetes.

Boehringer Ingelheim announced in June that it has compounds in Phase 2 and Phase 3 development for type 2 diabetes.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...